Protein microarray signature of autoantibody biomarkers for the early detection of breast cancer.

Abstact

Cancer patients spontaneously generate autoantibodies (AAb) to tumor-derived proteins. To detect AAb, we have probed novel high-density custom protein microarrays (NAPPA) expressing 4988 candidate tumor antigens with sera from patients with early stage breast cancer (IBC), and bound IgG was measured. We used a three-phase serial screening approach. First, a prescreen was performed to eliminate uninformative antigens. Sera from stage I-III IBC (n = 53) and healthy women (n = 53) were screened for AAb to all 4988 protein antigens. Antigens were selected if the 95th percentile of signal of cases and controls were significantly different (p < 0.05) and if the number of cases with signals above the 95th percentile of controls was significant (p < 0.05). These 761 antigens were screened using an independent set of IBC sera (n = 51) and sera from women with benign breast disease (BBD) (n = 39). From these, 119 antigens had a partial area under the ROC curve (p < 0.05), with sensitivities ranging from 9-40% at >91% specificity. Twenty-eight of these antigens were confirmed using an independent serum cohort (n = 51 cases/38 controls, p < 0.05). Using all 28 AAb, a classifier was identified with a sensitivity of 80.8% and a specificity of 61.6% (AUC = 0.756). These are potential biomarkers for the early detection of breast cancer.

Biomarkers

The following biomarkers make reference to this publication:

Protocols

One protocol is associated with this publication:

Authors
  • Anderson KS
  • Engstrom P
  • Godwin AK
  • Hainsworth E
  • Labaer J
  • Logvinenko T
  • Lokko N
  • Marks J
  • Mendoza EA
  • Montor WR
  • Park JG
  • Qiu J
  • Ramachandran N
  • Raphael J
  • Sibani S
  • Wallstrom G
  • Wong J
PubMed ID
20977275
Appears In
J Proteome Res, 2011, 10 (1)